Dec 05, 2019
Epic Sciences to Present New Data Showing Feasibility of its Liquid Biopsy Test in Breast Cancer
May 22, 2019
Epic Sciences Appoints New Chief Technology Officer
May 15, 2019
Epic Sciences to Present New Data Identifying Multiple Cancer Biomarkers Associated with Treatment Response in Prostate and Bladder Cancer at ASCO 2019
May 15, 2019
Slone Partners, Where People Are Our Science®, Places Richard Wenstrup, M.D., As Chief Medical Officer At Epic Sciences, Inc.
Apr 23, 2019
Epic Sciences Receives CE Mark for Liquid Biopsy Test Collection Kit
Apr 22, 2019
Epic Sciences Appoints Richard J. Wenstrup, M.D. as Chief Medical Officer
Apr 03, 2019
Epic Sciences Unveils New Liquid Biopsy Test to Predict Sensitivity to PARP Inhibitors in Prostate Cancer Trial
Mar 25, 2019
Epic Sciences Appoints Lloyd Sanders as Chief Executive Officer
Mar 21, 2019
Epic Sciences to Present New Data at AACR 2019 Demonstrating Expansion of Functional Cell Profiling Technology into New Indications including Breast, Lung and Prostate Cancer
Mar 20, 2019
Epic Sciences Announces Completion of New York State Licensure to Provide the Oncotype DX AR-V7 Nucleus Detect Test for Patients with Metastatic Castration-Resistant Prostate Cancer in New York State
Mar 13, 2019
Large Prospective Trial Validates Detection of AR-V7 Biomarker Using Epic Sciences' Platform to Predict Treatment Outcomes for Patients with Advanced Prostate Cancer
Feb 12, 2019
Epic Sciences to Present at ASCO-GU 2019 New Data Demonstrating Utility of Liquid Biopsy to Optimize Drug Development
Nov 28, 2018
Epic Sciences to Present Data at SABCS 2018
Sep 12, 2018
Epic Sciences Announces Completion of $52 Million Series E Financing
Sep 04, 2018
Epic Sciences Appoints Katherine Atkinson as Chief Commercial Officer
Jun 28, 2018
Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer
May 22, 2018
Epic Sciences Presents Single Cell Genomics Data at 10th DIA China Annual Meeting
May 16, 2018
Epic Sciences and Its Collaborators to Present New Data at ASCO 2018
May 11, 2018
Epic Sciences Presents Detection and Characterization of Rare Peripheral CTC Immunogenicity and T-Cell Activation
Mar 30, 2018
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect(TM) Test in Patients with Metastatic Castration-Resistant Prostate Cancer